FDA approves Astra Zeneca’s TRUQAP (capivasertib) plus fulvestrant for patients with advanced breast cancer Read More..

AstraZeneca’s TRUQAP (New Molecule Capivasertib) in combination with Faslodex (Fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive breast cancer. Truqap is film coated tablets 160mg / 200mg strength administered orally.